Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Learning Tree International Awarded Multi-Year Sole-Award NATO NCIA Commercial Training Services Contract – IFB-CO-423236 24-02-2026, 19:11

$152 Billion and Rising: New Report Shows Insurance Industry Facing Growing Average Annual Losses from Natural Catastrophes 2-09-2025, 16:00